100644-65-3Relevant articles and documents
Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors
Ouvry, Gilles,Clary, Laurence,Tomas, Lo?c,Aurelly, Michèle,Bonnary, Laetitia,Borde, Emilie,Bouix-Peter, Claire,Chantalat, Laurent,Defoin-Platel, Claire,Deret, Sophie,Forissier, Mathieu,Harris, Craig S.,Isabet, Tatiana,Lamy, Laurent,Luzy, Anne-Pascale,Pascau, Jonathan,Soulet, Catherine,Taddei, Alessandro,Taquet, Nathalie,Thoreau, Etienne,Varvier, Emeric,Vial, Emmanuel,Hennequin, Laurent F.
, p. 1561 - 1567 (2019)
Minor structural modifications - sometimes single atom changes - can have a dramatic impact on the properties of compounds. This is illustrated here on structures related to known mTOR inhibitor Sapanisertib. Subtle changes in the hinge binder lead to strikingly different overall profiles with changes in physical properties, metabolism, and kinase selectivity.
ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS
-
Paragraph 00339-00342, (2021/05/29)
The present disclosure provides adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease.
Fused pyrimidine derivatives substituted with a nitrogen-containing heterocyclic ring and their pharmaceutical use
-
Paragraph 0191-0196, (2021/07/17)
The present application relates to fused pyrimidine derivatives substituted with heterocycles containing nitrogen and to their medicinal use. Provided are a compound represented by chemical formula I, a solvate, a stereoisomer thereof, a pharmaceutically